The identification of novel molecular prognostic biomarkers and therapeutic targets for prostate cancer is fundamental toward improvement of patient outcome.
Introduction
Prostate cancer is the most frequently diagnosed cancer and the second leading cause of cancer-related deaths in the male population of the United States (1) . It has been reported that nearly 217,730 new cases of prostate cancer were diagnosed in the United States in 2010, among which 92% are present as local and low stage cases, as indicated by prostate specific antigen (PSA) testing (2) . To date, radical prostatectomy (RP) is the standard treatment for localized prostate cancer (3) . However, about 25-50% post-RP patients on long-term follow-up have biochemical recurrence (BCR) (4) . This is generally the earliest indicator of the recurrence. Therefore, the early risk detection of BCR with sensitive methods and specific tumor markers may effectively improve the prognosis of prostate cancer patients.
Androgen has been reported to play a pivotal role in androgen pathways and prostate carcinogenesis (5) . Androgen receptor (AR) regulates androgen-dependent gene transcription (6) . Many AR-regulated genes are crucial regulators of prostate development and maintenance (7) . Recently, emerging evidence suggests the potential involvement of altered regulation of microRNAs (miRNAs) in AR signaling and the pathogenesis of prostate cancer (8) (9) (10) (11) ).
MiRNAs are short, endogenous RNAs in cells, promoting translational repression and/or destabilizing target mRNAs, to optimize protein levels in numerous biological 
Intracellular Caspase and Caspase-3 Activities. Intracellular Caspase and
Caspase-3 assays were performed as described previously (32) . Activities of the total caspase and caspase-3 were assayed with CaspGLOW Fluorescein Caspase Staining kit and CaspGLOW Fluorescein Caspase-3 Staining kit (BioVision, Mountain View, CA), respectively, and detected by FACScalibur flow cytometer.
Tissue microarray (TMA) construction. TMA construction was performed as described previously (33) . Two replicate tumor samples (1 mm in diameter) were taken from the donor tissue blocks in a highly representative fashion and arrayed into a recipient paraffin block (35 mm × 622 mm × 65 mm) with a tissue microarrayer (Beecher Instrument Inc, WI, USA), as described by Kononen (34) .
LNA-ISH and Immunohistochemistry of TMA. Locked nucleic acid in situ hybridization (LNA-ISH) was performed as described previously (33) on a set of prostate cancer TMA slides using LNA TM probes for miR-133b (Exiqon, Vedbaek, Denmark; sequence: /5DigN/TAGCTGGTTGAAGGGGACCAAA/3Dig_N/).
Expression of RB1CC1 was detected in immunohistochemistry assays performed as
Research. described previously (35) , with polyclonal antibody for RB1CC1 (1:100, Proteintech).
Image acquisition and management. Digital images were captured using Nikon DS-Ri1 ECLIPSE Series (Nikon, Tokyo, Japan) with a 10 × objective. TMA images were managed using NIS Element D4.00 software (Nikon).
Statistical analysis. The BCR-free survival time was defined as the time from the date of surgery to that of BCR, and the follow-up data were updated till November 2012. The differential expressions of RB1CC1 between groups were analyzed using Ȥ 2 analysis. The probability of survival was estimated according to the Kaplan-Meier 
Results
Androgen induces the expression of miR-133b. We have previously analyzed miRNA and mRNA expression in LNCaP cells treated with 10 nM DHT at different time points (23) . cDNAs reverse transcribed from total RNAs at each time point were hybridized to Illumina Sentrix Human WG-6_V2 expression BeadChip arrays (for mRNA) or MicroRNA Expression Profiling Panels (for miRNA). The raw data have been uploaded to the Gene Expression Omnibus public repository (http://www.ncbi.nlm.nih.gov/geo/; Gene Expression Omnibus series no. GSE21245).
Data pre-processing, filtering criteria and statistical analysis were as described in (23) .
Of the 137 differentially expressed miRNAs, miR-133b was found to be androgen-responsive in early stage after DHT stimulation (20 min, 8 h), and had higher ARE enrichment according to genomatix database prediction (36) . Further, miRDB database was applied to predict the sequence-based miRNA targets (37) , which were also androgen-responsive genes, and GenMAPP for the pathway enrichment of miR-133b. As a result, miR-133b was valued with significant pathway enrichment in key cellular processes, such as regulation of cell size, cell growth, and cell cycle (p<0.05, data not shown).
Our microarray data analysis identified miR-133b to be up-regulated before 4 h, with a peak at 1 h after DHT stimulation (Fig. 1A) . Further validation of miR-133b expression was performed by qRT-PCR in LNCaP cells under the same experimental conditions. The expression of miR-133b was increased compared to the vehicle control (Fig. 1B) were used as positive controls ( Supplementary Fig. S1A-B) .
Differential expression of miR-133b in prostatic cell lines. Next, we evaluated the basal expression of miR-133b in noncancerous prostatic cells WPMY-1 and four prostate cancer cell lines LNCaP, 22Rv1, PC-3 and DU145. LNCaP is androgen-dependent prostate cancer (ADPC) cell line; 22Rv1 is weakly androgen-dependent; PC-3 is androgen-independent prostate cancer (AIPC) cell line without AR expression; and DU145 is AIPC cell line with AR expression. We observed that the less aggressive LNCaP cells had the least expression of miR-133b, whereas the more aggressive PC-3 cells showed the highest expression, which was 395.5-fold over that of LNCaP cells (Fig. 1C) . The finding raised the possibility that differentially expressed miR-133b might contribute to the progression of prostate cancer. In this study, we focused on miR-133b and investigated its involvement in prostate cancer.
Verification the binding of AR to miR-133b. As we have confirmed the expression of miR-133b is up-regulated by androgen, we wondered whether AR could bind to the DNA region of the miR-133b locus. We used Genomatix database (36) to predict AREs within the upstream and downstream 10 kb from pre-miR-133b's transcription start site. Seven AREs, formed 5 clusters (named A-E), were detected in the proximal DNA regions of miR-133b (Fig. 1D) . By ChIP-qPCR, we found that AR recruitment onto six out of seven AREs was induced significantly after 100 nM DHT stimulation 
MiR-133b influenced cell proliferation and cell cycle status of prostate cancer.
Since miR-133b was directly regulated by AR, we analyzed the role of miR-133b on various cellular processes of prostate cancer. Firstly, we evaluated the effect of miR-133b on cell proliferation of LNCaP, 22Rv1 and PC-3 cells. These cells were transfected with miR-133b mimics (miR-133bm), or anti-miR-133b (si133b). We observed that when cells were treated with miR-133bm, cell proliferation was significantly increased, compared with miR-NC in LNCaP and 22Rv1 cells ( Fig. 2A and 2C); whereas anti-miR-133b partially decreased cell proliferation, compared with anti-miR-NC in these two cell lines ( Fig. 2B and 2D ). In contrast, in PC-3 cells, miR-133bm inhibited cell proliferation; whereas si133b boosted cell proliferation ( decrease in G1 phase, compared with miR-NC; whereas knockdown of miR-133b resulted in a reduction in S phase, and an increase in G1 phase ( Fig. 2G and Supplementary Fig. S2A ). However, in PC-3 cells, miR-133bm caused an increase in G1 phase and a decrease in S phase; si133b decreased the proportion of cells in G1 phase and increased the proportion in S phase ( Fig. 2H and Supplementary Fig. S2C ).
The transfection efficiency of these assays was shown in Supplementary Fig.S2B MiR-133b affected cell apoptosis of prostate cancer. We further explored the role of miR-133b on cell apoptosis of prostate cancer. LNCaP and PC-3 cells were treated with miR-133bm, si133b, or their negative control, respectively, and followed by flow cytometry analyses. In LNCaP cells, miR-133bm boosted the fraction of living cells, and decreased that of late apoptotic cells, compared with the miR-NC; whereas si133b increased both the fraction of early apoptotic and late apoptotic cells (Fig. 3A and Supplementary Fig. S3A ). On the other hand, in PC-3 cells, miR-133bm reduced the fraction of living cells, and boosted that of late apoptotic cells; but si133b increased the proportion of living cells, and decreased that of late apoptotic cells ( Fig. 3B and Supplementary Fig. S3C ). The transfection efficiency of these assays was shown in Supplementary Fig. S3B and S3D.
In order to clarify the mechanism by which miR-133b affected cell apoptosis of prostate cancer, we detected the activity of total caspase and caspase-3 in LNCaP and PC-3 cells. In LNCaP cells, miR-133bm significantly reduced the fractions of activated caspase (Fig. 3C and Supplementary Fig. S4A ) and caspase-3 ( Fig. 3E and Supplementary Fig. S4E ), as compared with miR-NC; however, si133b boosted the proportion of activated caspase. In PC-3 cells, miR-133bm significantly increased the fractions of activated caspase ( Fig. 3D and Supplementary Fig. S4C ) and caspase-3 ( Fig. 3F and Supplementary Fig. S4G) ; whereas, si133b decreased the proportion of activated caspase. The transfection efficiency was shown in Supplementary Fig. S4B , S4D, S4F, and S4H, respectively. Taken together, we found that miR-133b functioned as an oncomiR, which promoted cell proliferation and suppressed apoptosis of ADPC cells LNCaP; however, this miR acted as a tumor suppressor by inhibiting cell proliferation and promoting apoptosis of AIPC cells PC-3.
RB1CC1 is a target of miR-133b. To identify potential target of miR-133b, we conducted a computational screen for genes with complementary sites of miR-133b in their 3'UTR using open-access software (TargetScan (www.targetscan.org), PicTar (http://pictar.bio.nyu.edu), and miRDB (www.mirdb.org)). We have performed expression profile in LNCaP cells and found several androgen-responsive miRNAs and mRNAs. To precisely evaluate the actual regulation of each predicted miRNA-mRNA pair, the Modulation Score (MS) was proposed (23) . For each predicted miRNA-mRNA pair whose members were both androgen-responsive, MS was calculated and the p value for each MS was evaluated. Subsequently, four
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mRNAs were identified as candidate targets of miR-133b: RB1CC1, PTPRK, SESN1, and CPNE3. qRT-PCR analysis in LNCaP cells indicated that the expression of RB1CC1 was the most significantly affected by overexpression or knockdown of miR-133b among these putative targets (Supplementary Fig. S5A ). Further, we focused on RB1CC1, which was reported to be a tumor suppressor and activate the expression of RB1 in breast cancer (38) , but its role in prostate cancer is unclear.
In order to confirm RB1CC1 as the direct target of miR-133b, we performed luciferase assays in LNCaP cells. There is a miR-133b eight-nucleotide seed match region at position 252-259 of the RB1CC1 3'-UTR (Fig. 4A) . Co-transfection of LNCaP cells with the wild-type 3'-UTR-reporter and miR-133bm showed significantly decreased luciferase activity as compared with miR-NC (Fig. 4B) .
Interaction between the binding-site in RB1CC1 3'-UTR and miR-133b was sequence-specific, since mutation of the seed sequence restored luciferase activity to values comparable to the empty vector (Fig. 4B) . These results denoted that the 3' UTR of RB1CC1 transcript was a target of miR-133b.
Ectopic expression of miR-133b affected endogenous RB1CC1. After we transiently transfected LNCaP, 22Rv1 and PC-3 cells with miR-133m, si133b, or their negative controls, respectively, miR-133bm was shown to decrease the mRNA and protein level of RB1CC1, relative to miR-NC; whereas si133b increased the mRNA and protein level of RB1CC1, compared with siNC ( Fig. 4C-D and Supplementary Fig.   S5C ).
To further address the physiological relationship between endogenous miR-133b and RB1CC1 in prostate cancer cells, RB1CC1 protein level and miR-133b expression were evaluated by western blot (Fig. 4E ) and qRT-PCR (Fig. 4F) Fig. S6A-B) , similar to that observed in the overexpression of miR-133b (Fig. 2G) .
Cell apoptosis analysis revealed that knockdown of RB1CC1 boosted the fraction of A previous study demonstrated that EGFR was a target of miR-133b in prostate cancer (42) . In line with their results, we found miR-133b downregulated the expression of EGFR in LNCaP and PC-3 cells (Fig.S5D-E) . Further experiments will be necessary to clarify whether RB1CC1 is the target of miR-133b in HeLa cells.
Notably, recent studies suggested that RB1CC1 could represent a potential diagnosis and drug target for a broad range of cancers. Nuclear expression of RB1CC1 was shown to predict a better clinical outcome in salivary gland cancers (44) . In breast cancer, RB1CC1 was reported to predict long-term survival together with RB1 and p53 (45) . Based on our results, we speculated that RB1CC1 might function as a tumor suppressor, which was opposite to the oncomiR role of miR-133b in ADPC cells
LNCaP, yet further study is needed to fully illustrate the function of RB1CC1 in AIPC cells.
To our knowledge, this is the first study showing the significance of miR-133b and RB1CC1 in relation to clinical data on patients with prostate cancer. We found that the expression of miR-133b and RB1CC1 protein were inversely correlated. Because none of the patients involved in our study received any pre-operation treatment, the clinical samples can be regarded as androgen dependent. Hence, our findings in patients' specimens confirmed the results we obtained in ADPC cells LNCaP, which indicated an oncomiR role of miR-133b and a tumor suppressor function of RB1CC1.
Finally, multivariate Cox hazard regression analysis revealed that miR-133b and RB1CC1 were identified as independent prognostic factors of outcome for prostate cancer patients after RP.
Despite the combination of increasingly refined surgical techniques and reduced incidence of surgical complications, the variable disease course leads to eventual 
